trending Market Intelligence /marketintelligence/en/news-insights/trending/nOHegqD_o4ZuHyy9c-vuow2 content esgSubNav
In This List

Biom'Up raises €38.1M in IPO to fund blood clotting products

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


Biom'Up raises €38.1M in IPO to fund blood clotting products

Biom'Up said it raised €38.1 million in an initial public offering on the Euronext Exchange following strong demand from French, U.K. and U.S. investors.

The French medical company, which develops products to stop bleeding during surgery, priced its shares at €10.5 apiece for a market capitalization of €113 million.

Biom'Up intends to use the proceeds partly to prepare for the U.S. launch of its Hemoblast Bellows product, which helps blood coagulate during surgery.

The product is under review at the U.S. Food and Drug Administration with a decision expected in mid-2018.

Biom'Up shares will be admitted to the Euronext Exchange and start trading Oct. 13.

The company is the first healthcare group to IPO on the exchange in six months.